Impact of Formulary Coverage of Entresto (Sacubitril/Valsartan) on Prescription Abandonment/Rejection and Subsequent Treatment and Economic Outcomes in Chronic Heart Failure Patients in the U.S.

Inclusion Criteria: Primary IQVIA Longitudinal Access and Adjudication Data (LAAD) Cohort (for primary objective) * Patients with ≥1 transaction for SAC/VAL in LAAD between 01 January 2017 and 30 November 2019 (index period). Date of the 1st SAC/VAL prescription transaction during this period was the index date. * Patients from the Novartis-provided list of 21 plans and formularies of interest (mapping to LAAD data was based data elements such as plan name, payer name, and pharmacy benefit manager \[PBM\] name) as of the index date. * Patients aged ≥18 years on the index date. * Patients with 12-months of data visibility pre-index. * Patients with 3-months of data visibility post-index (to allow for final adjudication/abandonment status confirmation). For comorbidity data only: * Patients with linkage of LAAD FIA to LAAD Dx by patient ID. * Patients with ≥2 non-ancillary medical claims ≥30 days apart within the 12 months pre-index period. Secondary LAAD Cohort (for secondary objective) * Among patients from the Primary LAAD Cohort remaining in Step 6, patients who abandoned their 1st SAC/VAL prescription or did not receive SAC/VAL due to claim rejection in LAAD between 01 January 2017 and 28 February 2019 (index period). Date of the 1st abandoned/rejected SAC/VAL prescription transaction during this period is the index date. * Patients aged ≥18 years on the index date. * Patients with 12-months of data visibility pre-index. * Patients with 12-months of data visibility post-index. * For comorbidity data only: * Patients with linkage of LAAD FIA to LAAD Dx by patient ID. * Patients with ≥2 non-ancillary medical claims ≥30 days apart within the 12 months pre-index period. Exclusion Criteria: * Patients with a SAC/VAL transaction during the 12-month pre-index period. * Patients with data quality issues (e.g., missing gender).